机构：[1]Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China[2]Huanghuagang Street Community Health Service Center, Guangzhou, People’s Republic of China[3]Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College of Xiamen University, Xiamen, People’s Republic of China[4]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China临床科室其他部门放疗科华南肿瘤学国家重点实验室中山大学肿瘤防治中心
To investigate the effect of distant metastases sites on survival in patients with de novo stage-IV breast cancer. From 2010 to 2013, patients with a diagnosis of de novo stage-IV breast cancer were identified using the Surveillance, Epidemiology, and End Results database. Univariate and multivariate Cox regression analyses were performed to analyze the effect of distant metastases sites on breast cancer-specific survival and overall survival. A total of 7575 patients were identified. The most common metastatic sites were bone, followed by lung, liver, and brain. Patients with hormone receptor+/ human epidermal growth factor receptor 2-and hormone receptor+/human epidermal growth factor receptor 2+ status were more prone to bone metastases. Lung and brain metastases were common in hormone receptor-/human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2-subtypes, and patients with hormone receptor+/human epidermal growth factor receptor 2+ and hormone receptor-/human epidermal growth factor receptor 2+ subtypes were more prone to liver metastases. Patients with liver and brain metastases had unfavorable prognosis for breast cancer-specific survival and overall survival, whereas bone and lung metastases had no effect on patient survival in multivariate analyses. The hormone receptor-/human epidermal growth factor receptor 2-subtype conferred a significantly poorer outcome in terms of breast cancer-specific survival and overall survival. hormone receptor+/human epidermal growth factor receptor 2+ disease was associated with the best prognosis in terms of breast cancer-specific survival and overall survival. Patients with liver and brain metastases were more likely to experience poor prognosis for breast cancer-specific survival and overall survival by various breast cancer subtypes. Distant metastases sites have differential impact on clinical outcomes in stage-IV breast cancer. Followup screening for brain and liver metastases might be effective in improving breast cancer-specific survival and overall survival.
基金：
Sci-Tech Office of Guangdong Province [2013B021800157, 2013B021800458]; Natural Science Foundation of Fujian Province [2016J01635]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|3 区肿瘤学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构：[3]Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Medical College of Xiamen University, Xiamen, People’s Republic of China[4]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China
推荐引用方式(GB/T 7714)：
Wu San-Gang,Li Hui,Tang Li-Ying,et al.The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis[J].TUMOR BIOLOGY.2017,39(6):1-8.doi:10.1177/1010428317705082.
APA：
Wu, San-Gang,Li, Hui,Tang, Li-Ying,Sun, Jia-Yuan,Zhang, Wen-Wen...&He, Zhen-Yu.(2017).The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.TUMOR BIOLOGY,39,(6)
MLA：
Wu, San-Gang,et al."The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis".TUMOR BIOLOGY 39..6(2017):1-8
